You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Mixed Anxiety Depression Should Not Be Included in DSM-5

Batelaan, Neeltje M. MD, PhD*†; Spijker, Jan MD, PhD‡§∥; de Graaf, Ron PhD; Cuijpers, Pim PhD†¶

Journal of Nervous & Mental Disease:
doi: 10.1097/NMD.0b013e318257c4c9
Original Article
Abstract

Abstract: Subthreshold anxiety and subthreshold depressive symptoms often co-occur in the general population and in primary care. Based on their associated significant distress and impairment, a psychiatric classification seems justified. To enable classification, mixed anxiety depression (MAD) has been proposed as a new diagnostic category in DSM-5. In this report, we discuss arguments against the classification of MAD. More research is needed before reifying a new category we know so little about. Moreover, we argue that in patients with MAD symptoms and a history of an anxiety or depressive disorder, symptoms should be labeled as part of the course trajectories of these disorders, rather than calling it a different diagnostic entity. In patients with incident co-occurring subthreshold anxiety and subthreshold depression, subthreshold categories of both anxiety and depression could be classified to maintain a consistent classification system at both threshold and subthreshold levels.

Author Information

*Department of Psychiatry, VU University Medical Center and GGZ inGeest, Amsterdam, The Netherlands; †EMGO-Institute, VU University and VU University Medical Center, Amsterdam, the Netherlands; ‡Netherlands Institute of Mental Health and Addiction, Utrecht, the Netherlands; §Pro Persona, Ede, the Netherlands; ∥Department of Clinical Psychology, Radboud University, Nijmegen, the Netherlands; and ¶Department of Clinical Psychology, VU University, Amsterdam, the Netherlands.

Editor’s note: Proposed DSM-5 criteria sets do not represent the final DSM-5 criteria for the disorders.

Send reprint requests to Neeltje M. Batelaan, MD, PhD, Department of Psychiatry and EMGO-Institute, VU University Medical Center and GGZ inGeest, A.J. Ernststraat 1187, 1081 HL Amsterdam, The Netherlands. E-mail: n.batelaan@ggzingeest.nl.

© 2012 Lippincott Williams & Wilkins, Inc.